12 December 2022

An analysis of the latest treatments for diffuse large B cell lymphoma (DLBCL) predicts high competition from a large number of upcoming drugs.

The data analytics company GlobalData says there are more than 255 products currently at the clinical trial stage for the treatment of DLBCL, the most common form of non-Hodgkin’s lymphoma.

Dr Avigayil Chalk of GlobalData said: “Three autologous anti-CD19 Chimeric antigen receptor T cell (CAR-T) therapies, Gilead’s Yescarta, Novartis’ Kymriah, and BMS’ Breyanzi have gained US Food and Drug Administration approval for the treatment of relapsed or refractory diffuse large B cell lymphoma.

“This success has particularly fuelled research in the field of gene-modified cell therapies, with 96 agents of this class currently being trialled.”

But she adds that major limitations exist for the currently approved CAR-Ts, including personalised manufacture, high price, and the requirement for specialist medical centres.

She said: “Pipeline gene-modified cell therapies will either have to demonstrate superior efficacy to currently approved CAR-Ts or address one of these limitations to gain approval in this competitive setting.”

On the other hand, allogeneic CAR natural killer (CAR-NK) therapeutics avoid the need for personalised manufacture.

This allows up-scaling of production, which drives price down, increases the number of patients that can be treated, and reduces the time to therapy initiation, Dr Chalk points out.

Such agents appear very promising in early phase trials, and research findings over the next three years are crucial for determining their future potential.

Overall, the GlobalData report highlights a continuing high level of unmet need in this disease with a challenging pathway to regulatory approval for new therapeutic agents.

Source: GlobalData


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News.